Trethera Corp
Discover Trethera’s breakthrough therapy TRE-515 for autoimmune, oncology, and neuroinflammatory diseases. Learn about our science-driven innovation.
Funding history
About Trethera Corp
How much funding has Trethera Corp raised?
Trethera Corp has raised $250K in total funding. The most recent round was Seed.
Where is Trethera Corp headquartered?
Trethera Corp is headquartered in Sherman Oaks, CA.
What does Trethera Corp do?
Discover Trethera’s breakthrough therapy TRE-515 for autoimmune, oncology, and neuroinflammatory diseases. Learn about our science-driven innovation.
What problem does Trethera Corp solve?
Many patients with cancer and autoimmune diseases face limited treatment options with severe side effects.
What's Trethera Corp's solution?
Trethera is developing TRE-515, a first-in-class dCK inhibitor pill designed to target these diseases at their root more safely and effectively.
What makes Trethera Corp different?
TRE-515 is the only drug with FDA Orphan Drug status in pediatric ADEM, was discovered by UCLA scientists, received a $2M NIH SBIR grant, and its Phase 1a trial showed no dose-limiting toxicities up to 320mg with favorable pharmacokinetics.
What makes Trethera Corp notable?
Trethera is a UCLA spinout founded by UCLA scientists, built on an exclusive license to a cancer/autoimmune drug patent (dCK inhibitor TRE-515) invented by UCLA professor Dr. Peter M. Clark.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.